



[Print this Page for Your Records](#)

[Close Window](#)

**Control/Tracking Number:** 2021-A-258-ACRIMS

**Activity:** Abstract

**Current Date/Time:** 10/30/2020 1:29:39 AM

**Patient and Nurse Preferences for Sensoready® Autoinjector Pen Versus Other Autoinjectors in Multiple Sclerosis: Results from a Multicenter Survey**

**Author Block:** A. Ross<sup>1</sup>, C. Besser<sup>2</sup>, S. Naval<sup>3</sup>, D. Stoneman<sup>2</sup>, H. Gaunt<sup>4</sup>, N. Barker<sup>5</sup>;

<sup>1</sup>Loyola University Medical Center, Chicago, IL, <sup>2</sup>Novartis Pharma AG, Basel, SWITZERLAND, <sup>3</sup>Novartis Healthcare Private Limited, Hyderabad, INDIA, <sup>4</sup>Adelphi Research, Bollington, UNITED KINGDOM, <sup>5</sup>University College London Hospitals, London, UNITED KINGDOM.

**Abstract:**

**Background:** Convenience of treatment administration plays an important role in patient satisfaction and consequently, adherence. Using a prefilled syringe assembled with an autoinjector Sensoready® pen facilitates the self-administration of subcutaneous (SC) ofatumumab injections at home.

**Objectives:** To investigate patient and nurse preference for using the Sensoready pen for SC administration of ofatumumab 20 mg versus other autoinjectors used for other disease-modifying therapies (DMTs) in multiple sclerosis (MS).

**Methods:** The survey was conducted in 2 phases—central location pilots (Germany) followed by face-to-face semi-structured in-field interviews across USA, Germany, France, and Italy—to recruit 80 MS patients and 50 MS nurses at offices, hospital-based practices, and specialist MS centers. Relapsing-remitting MS patients who received DMT through a SC/intramuscular injection via autoinjector for ≥2 months were included. Specialist MS nurses who had ≥3 years of practice, >80% time spent in clinical practice, and experienced in training patients on ≥2-6 MS autoinjector devices (Rebifose/Rebismart [Rebif], Avonex pen [Avonex], Autoject/YpsoMate [Copaxone], Plegridy pen [Plegridy]) were recruited. Respondents were interviewed for 45 minutes on qualitative open-ended and quantitative close-ended questions (31 for patients; 41 for nurses) to rate the importance of predefined attributes for Sensoready versus other autoinjectors. The ratings were measured on Likert scale from 1 (not at all important) to 10 (extremely important).

**Results:** Recruited MS patients were an average age of 43 years and had ~7 years of disease duration; nurses had spent an average of 15 years (4-34 range) in practice. Overall, “easy to perform the self-injection with the pen” (9.4) and “patient able to use independently” (9.4) attributes for autoinjectors were ranked the highest by both patients and nurses. Sensoready scored highly across the majority of attributes (>8.0 out of a possible 10) versus other autoinjectors and was similarly rated by both nurses and patients. “easy to perform the self-injection with the pen” (9.4), “patient able to use independently” (9.4), and “ease of preparation and set-up” (9.4) were the highest ranked, while “pen is reusable” (6.4;  $p < 0.05$ ) was ranked significantly lower versus other attributes. Majority of participants preferred Sensoready versus their current device (84% vs 16%;  $p < 0.05$ ), and response was similar for both nurses (86%) and patients (83%). The preference rates for the Sensoready attributes ranged from 39% to 91%, with the highest rates recorded for “easy to perform self-injection with the pen” (91%) and “process required to start injection” (87%).

**Conclusions:** Results suggest that both MS patients and nurses prefer Sensoready® autoinjector pen for ofatumumab 20 mg SC administration over other autoinjectors for their current treatment(s), mostly driven by ease of administration.

:

**Additional (Complete):**

**Are you a Young Investigator?:** No

**Highly rated submissions will be considered for a platform presentation. If selected, are you willing to make a platform presentation?:** Yes

**Would you like to present your poster to a small group for discussion?:** Yes

**Are you a National MS Society Fellow?:** Yes

**Are you a Canadian MS Society Fellow?:** No

**Are you a member of North American Imaging in Multiple Sclerosis Cooperative (NAIMS):?** No

**Are you a member of International Multiple Sclerosis Visual System Consortium (IMSVISUAL):?** No

**Keyword (Complete):** Patient-Reported Outcomes and Quality of Life

**Status:** Finalized

Feedback

Powered by [cOASIS](#), The Online Abstract Submission and Invitation System <sup>SM</sup>  
© 1996 - 2020 [CTI Meeting Technology](#). All rights reserved. [Privacy Policy](#).